Late-Stage Pipeline Call

AstraZeneca will host a call for investors and analysts on 2 December 2015 from 4:00pm - 5:30pm GMT (11:00am - 12:30pm EST). The call will focus on key potential medicines within the late-stage pipeline and will provide further details on the progress made in 2015 and the anticipated newsflow in 2016. No material new information will be included; the call is intended to offer additional insight on the pipeline. The event will be led by Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer alongside AstraZeneca experts from each of the Company’s main therapy areas.

If you wish to listen to the presentation and take part in the Q&A session live, please see the details below:

UK

0800 694 2370

US

866 977 7645

International

+44 1452 557749

Sweden

0200 883 079

Code

79258160

 

The presentation will be available for download at astrazeneca.com/investors one hour prior to the start of the call.

Audio webcast

Listeners will be able to pre-register and test the webcast via astrazeneca.com/investors from Monday 30 November. During the Q&A session listeners will be able to pose questions to the presenters via e-mail. If you wish to participate in the Q&A session live rather than by e-mail you will need to dial in to the call. Details are shown above.

An indexed version of the webcast will be available from 5:30pm GMT on 3 December 2015 at astrazeneca.com/investors.

Replay

A replay of the call will be available from 5:30pm GMT on 2 December 2015 to close of business on 24 December 2015. This will be accessible via the following numbers:

 

UK

0800 953 1533

US

866 247 4222

International

+44 1452 550000

Code

79258160

 

A transcript of the call will be made available at astrazeneca.com/investors.

We do hope you can join us for the call.

 

With kind regards,

Mary Pericleous

On behalf of the AstraZeneca Investor Relations Team